Jazz Pharmaceuticals plc (JAZZ)
As-reported financials and SEC filings for Jazz Pharmaceuticals plc. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that develops and markets medicines for rare diseases, including epilepsies, cancers, and sleep disorders. Its main products include Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex for seizures associated with rare epilepsy syndromes, and Ziihera for HER2-positive biliary tract cancer. The company serves patients with rare conditions who often have limited or no therapeutic options.
Snapshot
Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
What changed at Jazz Pharmaceuticals
- Revenue grew 4.9% to $4.3B in FY2025, in line with the 6.1% the year before.
- Operating margin is now a 10.1% loss in FY2025, from 5.5% in FY2021.
- Most recent quarter Q2 FY2026: revenue $1.2B, up 15.5% from Q2 FY2025.
- Free cash flow was $1.3B in FY2025, 30.4% of revenue.
- Net income turned to a $356M loss in FY2025, from a $560M profit in FY2024.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Jazz Pharmaceuticals’s fundamentals sit among the 198 pharmaceutical companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
Jazz Pharmaceuticals’s FCF margin of 30.4% ranks in the 90th percentile of the 110 pharmaceutical companies reporting it.
No reported insider purchases (code P) in the last 90 days; 12 insider sales totaling $24.9M. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →
Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.
Recent insider activity
Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.
| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
2026-10-06 filed 2026-10-07 | Renee D. GalaPresident & CEO | Sell | 2.0K | $236.40 | $473K |
2026-10-01 filed 2026-10-05 | Bruce C. CozaddDirector | Sell | 6.0K | $230.33 | $1.4M |
2026-09-10 filed 2026-09-14 | Neena M. PatilEVP & Chief Legal Officer | Sell | 1.2K | $240.94 | $289K |
2026-09-08 filed 2026-09-10 | Renee D. GalaPresident & CEO | Sell | 2.0K | $243.03 | $486K |
2026-09-01 filed 2026-09-02 | Bruce C. CozaddDirector | Sell | 6.0K | $250.13 | $1.5M |
2026-08-27 filed 2026-08-31 | Robert IannoneEVP, Global Head of R&D & CMO | Sell | 19.6K | $250.60 | $4.9M |
2026-08-27 filed 2026-08-31 | Robert IannoneEVP, Global Head of R&D & CMO | Sell | 18.1K | $250.02 | $4.5M |
2026-08-27 filed 2026-08-31 | Robert IannoneEVP, Global Head of R&D & CMO | Sell | 18.2K | $247.86 | $4.5M |
2026-08-27 filed 2026-08-31 | Robert IannoneEVP, Global Head of R&D & CMO | Sell | 11.4K | $248.67 | $2.8M |
2026-08-27 filed 2026-08-31 | Robert IannoneEVP, Global Head of R&D & CMO | Sell | 9.3K | $251.95 | $2.3M |
2026-08-27 filed 2026-08-31 | Robert IannoneEVP, Global Head of R&D & CMO | Sell | 300 | $252.76 | $76K |
2026-08-03 filed 2026-08-05 | Bruce C. CozaddDirector | Sell | 6.0K | $252.98 | $1.5M |
Reported non-derivative purchases and sales (codes P/S), which may be open-market or private. Excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-09-30 | 5.5M | +17.2% | 6.48 |
| 2026-09-15 | 4.7M | +1.1% | 7.22 |
| 2026-08-31 | 4.6M | +27.9% | 3.68 |
| 2026-08-14 | 3.6M | +7.7% | 3.81 |
| 2026-07-31 | 3.4M | -11.8% | 5.33 |
| 2026-07-15 | 3.8M | +8.6% | 4.83 |
| 2026-06-30 | 3.5M | -11.2% | 3.75 |
| 2026-06-15 | 3.9M | -8.1% | 4.24 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Gross profit | — | — | — | — | — |
| Operating income | $-430.2M | $716.6M | $578.6M | $-65.5M | $170.3M |
| Net income | $-356.1M | $560.1M | $414.8M | $-224.1M | $-329.7M |
| Diluted EPS | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.
Balance sheet (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Cash and equivalents | $1.39B | $2.41B | $1.51B | $881.5M | $591.4M |
| Current assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B |
| Total assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B |
| Current liabilities | $2.24B | $1.04B | $1.54B | $933.2M | $809.3M |
| Long-term debt | $4.33B | $6.08B | $5.11B | $5.69B | $6.02B |
| Total liabilities | |||||
| Total equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.
Cash flow (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating cash flow | $1.36B | $1.40B | $1.09B | $1.27B | $778.5M |
| Capital expenditure | $58.8M | $38.1M | $24.0M | $29.0M | $27.6M |
| Free cash flow |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.
Quarterly trend
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q2 FY2026 | $1.21B | 15.5% | $192.8M | $2.78 |
| Q1 FY2026 | $1.07B | 19.1% | $293.1M | $4.43 |
| Q4 FY2025 | 10.1% | |||
| Q3 FY2025 | $1.13B | 6.7% | $251.4M | $4.08 |
| Q2 FY2025 | $1.05B | 2.1% | $-718.5M | $-11.74 |
| Q1 FY2025 | $897.8M | -0.5% | $-92.5M | $-1.52 |
| Q4 FY2024 | 7.5% | |||
| Q3 FY2024 | $1.05B | 8.5% | $215.1M | $3.42 |
Latest 8 quarters, from company XBRL filings on SEC EDGAR. A dotted underline marks a fourth-quarter figure we calculated from the full year and the first nine months. Revenue YoY is our calculation too: each quarter against the same quarter a year earlier.
Company facts
Selected SEC filings
Largest pharmaceutical peers
Monitor JAZZ
Get an alert when Jazz Pharmaceuticals files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor JAZZ freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.